<DOC>
	<DOCNO>NCT01586624</DOCNO>
	<brief_summary>The purpose study determine whether use two drug together call vandetanib selumetinib effective treatment cancer . The first part study include patient solid tumour second part study include patient non small cell lung cancer . The four main aim clinical study find : - If two drug give safely patient give together . - The maximum dose give safely patient . - More potential side effect drug manage . - What happen vandetanib selumetinib inside body .</brief_summary>
	<brief_title>A Phase I Trial Vandetanib ( ZD6474 ) Selumetinib ( AZD6244 ) Solid Tumours Including Non Small Cell Lung Cancer ( VanSel-1 )</brief_title>
	<detailed_description>The purpose Phase I study establish safety toxicity profile combine two study drug ; vandetanib , VEGFR ( Vascular Endothelial Growth Factor Receptor ) EGFR ( Epidermal Growth Factor Receptor ) inhibitor , selumetinib MEK ( Mitogen Activated Kinase ) inhibitor . This first time drug use together . These type drug show effect non small cell lung cancer ( NSCLC ) therefore aim see combine drug increase anti-tumour effect group patient treatment option limit . The study two part ; dose escalation phase expansion cohort . In dose escalation phase , 9-50 patient receive vandetanib increase dos selumetinib establish safe dose recommend next stage study . Patients solid tumour eligible . In expansion cohort , approximately 30 patient receive dose recommend previous phase . Only patient NSCLC eligible part study . The expansion cohort look evaluate safety drug combination anti-tumour activity . Patients cohort request also consent additional imaging assessment optional tumour biopsy . Study treatment administer orally ; vandetanib tablet daily selumetinib capsule twice daily . Cycle 1 42 day long . Subsequent cycle 28 day length . Patients receive total 6 cycle combination treatment . If patient progress six cycle , may treat cycle follow approval sponsor .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . ( Dose escalation cohort ) Histologically cytologically proven solid tumour conventional therapy exists decline patient 2 . ( Expansion cohort ) Histologically cytologically confirm NSCLC patient , conventional therapy exists decline patient . If cytologically confirm , baseline biopsy mandatory patient eligible . For NSCLC patient eligible expansion cohort must receive : One prior line chemotherapy and/or Previous platinum base chemotherapy and/or At least one previous EGFR inhibitor 3 . ( Expansion cohort ) Measurable disease accord RECIST criterion Version 1.0 4 . Life expectancy least 12 week 5 . World Health Organisation ( WHO ) performance status 01 ( Appendix 1 ) 6 . Baseline LVEF &gt; 50 % 7 . Haematological biochemical index within range show . These measurement must perform within one week ( Day 7 Day 1 ) patient go study . Laboratory Test Value require Haemoglobin ( Hb ) ≥ 9.0 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Normal serum calcium ( adjust ) * 2.152.55 mmol/L Normal serum magnesium* 0.601.0 mmol/L Normal serum potassium &gt; 4.0 mmol/L Either : Serum bilirubin ≤1.5 x upper limit normal ( ULN ) This apply patient Gilbert‟s disease . Or : Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN unless raise due aspartate aminotransferase ( AST ) liver metastases case alkaline phosphatase ( ALP ) 5 x ULN permissible Either : Calculated creatinine clearance ( use Wright C &amp; G formula ) &gt; 50 mL/min Or : Isotope clearance measurement** ≥ 50 mL/min ( uncorrected ) INR aPTT &lt; 1.5 x ULN *or normal range accord local laboratory ** Isotope clearance result use confirm eligibility calculate C &amp; G/Wright method result GFR = 50 mL/min . 8 . 18 year 9 . Ability swallow retain oral medication . 10 . Written ( sign date ) inform consent capable cooperate treatment , followup 1 . Radiotherapy ( except palliative reason ) , endocrine therapy , immunotherapy chemotherapy previous 4 week ( 6 week investigational medicinal product ) treatment . 2 . Patients withdraw treatment agent target EGFR unacceptable toxicity ( prior treatment agent allow ) patient EGFR dose reduction . 3 . Prior treatment agent target MEK VEGFR 4 . Any prior exposure RAS RAF inhibitor 5 . Ongoing toxic manifestation previous treatment . Exceptions alopecia certain Grade 1 toxicity , opinion Investigator Drug Development Office ( DDO ) exclude patient . 6 . Symptomatic brain metastasis ( patient must stable &gt; 3 month post RT treatment ) spinal cord compression . 7 . Patients interstitial lung disease . 8 . Pregnant lactate woman exclude . Female patient ability become pregnant negative serum urine pregnancy test enrollment agree use two follow three highly effective form combine contraception ( oral , injected implant hormonal contraception condom , intrauterine device condom , diaphragm spermicidal gel condom ) four week enter trial , trial six month afterwards consider eligible . 9 . Male patient partner childbearing potential ( unless agree take measure father child use one form highly effective contraception [ condom plus spermicide ] trial six month afterwards ) . Men pregnant lactate partner advise use barrier method contraception ( e.g . condom plus spermicidal gel ) prevent exposure foetus neonate . 10 . Major surgery patient yet recover . 11 . At high medical risk nonmalignant systemic disease include active uncontrolled infection . 12 . Known serologically positive Hepatitis B , Hepatitis C Human Immunodeficiency Virus ( HIV ) . 13 . Cardiac condition follow : Clinically significant cardiovascular event within 3 month prior entry include : Myocardial infarction Angina require use nitrate weekly Superior vena cava syndrome Class II/III/IV cardiac disease ( New York Heart Association [ NYHA ] ) ( Appendix 4 ) Presence cardiac disease opinion Investigator increase risk ventricular arrhythmia . History arrhythmia symptomatic require treatment ( CTCAE 3 ) , symptomatic uncontrolled atrial fibrillation despite treatment asymptomatic sustain ventricular tachycardia . Patients atrial fibrillation control medication permit . Uncontrolled hypertension ( BP &gt; 160/100 despite optimal therapy ) Prior current cardiomyopathy Atrial fibrillation heart rate &gt; 100 bpm QTcB &gt; equal 450 msec screen ECG ( Note : If patient QTcB interval &gt; equal 450 msec screen ECG , screen ECG may repeat twice [ least 24 hour apart ] . The average QTcB three screen ECGs must &lt; 450 msec order subject eligible study . ) History congenital long QT syndrome History Torsade de Pointes ( concurrent medication know risk induce Torsades de Pointes . See Appendix 16.8 ) 14 . Concomitant medication potent inducer CYP3A4 function i.e . rifampicin , rifabutin , phenytoin , carbamazepine , Phenobarbital St John‟s Wort . 15 . Any condition Investigator‟s opinion would make patient good candidate clinical trial ( e.g . evidence severe uncontrolled systemic disease concurrent condition may affect ability absorb oral agent ) . 16 . Current malignancy type , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin . Cancer survivor , undergone potentially curative therapy prior malignancy , evidence disease five year deem negligible risk recurrence , eligible trial . 17 . If participant plan participate another interventional clinical study , whilst take part Phase I study . Participation observational study would acceptable . 18 . Ophthalmological condition follow : 1 . Current past history retinal pigment epithelial detachment ( RPED ) /central serous retinopathy ( CSR ) retinal vein occlusion . 2 . Intraocular pressure ( IOP ) &gt; 21 mmHg uncontrolled glaucoma ( irrespective IOP ) . 19 . ( Expansion cohort ) If patient unsuitable administration DCEMRI contrast material hypersensitivity impair renal function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Drug evaluation</keyword>
	<keyword>Oncology</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>Selumetinib</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Vascular Endothelial Growth Factor ( VEGFR ) inhibitor</keyword>
	<keyword>Epidermal Growth Factor Receptor ( EGFR ) inhibitor</keyword>
	<keyword>Mitogen Activated Kinase ( MEK ) inhibitor</keyword>
	<keyword>Non small cell lung cancer</keyword>
</DOC>